Drug intelligence / Profile preview

FT-4101

Development stage: Discontinued
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Oral

Overview

FT-4101 is a potent, selective, orally bioavailable small molecule inhibitor of fatty acid synthase (FASN), developed for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. It acts by inhibiting hepatic de novo lipogenesis (DNL), which is implicated in the pathogenesis of NASH and related metabolic disorders. Clinical studies have shown that FT-4101 can safely reduce hepatic DNL and improve liver fat content in patients with nonalcoholic fatty liver disease (NAFLD). The drug was initially developed by Forma Therapeutics, now a subsidiary of Novo Nordisk.

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)FASN (Fatty acid synthase)

Beyond the preview

Go deeper on FT-4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT-4101.

Explore the full profile